Sio Capital Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Sio Capital Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-468,871	Closed	-$2.31M	–	62
2024 Q1	$2.31M	Buy	+468,871	New	+$2.78M	0.69%	35
2023 Q4	–	Sell	-342,477	Closed	-$3.93M	–	60
2023 Q3	$3.93M	Buy	342,477 +200,977	+142%	+$3.86M	1.22%	25
2023 Q2	$3.58M	Buy	+141,500	New	+$4.41M	0.91%	23
2020 Q1	–	Sell	-87,700	Closed	-$1.42M	–	92
2019 Q4	$1.42M	Sell	87,700 -217,964	-71%	-$3.38M	0.34%	47
2019 Q3	$3.97M	Sell	305,664 -98,000	-24%	-$1.2M	1.28%	31
2019 Q2	$5.24M	Buy	403,664 +149,083	+59%	+$1.88M	1.26%	25
2019 Q1	$4.01M	Buy	254,581 +86,857	+52%	+$1.51M	1.08%	38
2018 Q4	$3.38M	Buy	167,724 +3,371	+2%	+$74.3K	1.23%	36
2018 Q3	$4.08M	Buy	164,353 +63,061	+62%	+$1.72M	1.4%	28
2018 Q2	$2.78M	Buy	+101,292	New	+$3.04M	1.54%	28

Other funds holding RVNC

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sio Capital Management's RVNC Position: Q2 2024 in Review

Sio Capital Management sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2024, closing a stake of 468,871 shares — an estimated $2.31M sold.

Sio Capital Management first reported a position in RVNC in Q2 2018 and held it in 10 quarters. The position peaked at $5.24M in Q2 2019. 173 funds tracked by Wall St. Rank hold RVNC as of Q2 2024.

Sio Capital Management reported no remaining Revance Therapeutics, Inc. position as of Q2 2024 after selling out during the quarter.
Sio Capital Management sold 468,871 Revance Therapeutics, Inc. shares in Q2 2024, an estimated $2.31M.
Sio Capital Management first reported a position in Revance Therapeutics, Inc. in Q2 2018 and held it in 10 quarters.
Sio Capital Management's Revance Therapeutics, Inc. position peaked at $5.24M in Q2 2019.
173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2024.

Based on Sio Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.